The company has ditched a trial of drebuxelimab plus ivonescimab.
ApexOnco Front Page
Recent articles
CRB-601 and PF-06940434 fall by the wayside.
But the Day One deal is still 29% below where the shares stood at the start of this year.
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
The response rate jumps to 30% with higher doses of IMA402.
New detalimogene bladder cancer data send the minnow’s stock up 47%.
After more discontinuations, a new deal brings in fresh blood.
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
